Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Holding stablecoins as a cash position can boost liquidity while reducing volatility. This short explanation highlights benefits and use cases.
24,798 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
A hedge fund manager publicly admits that his temperament blocks Buffett-style value investing. The admission highlig...
JPMorgan raised its price target on Dell Technologies to 280 amid easing memory headwinds and a robust AI server back...
Inflation data hints that the 2027 cost of living adjustment could be larger for retirees. Yet, higher Medicare premi...
Former White House adviser Kevin Hassett publicly endorses Fed Chair nominee Kevin Warsh's policy plan, signaling a s...
A coalition of fair housing and economic justice groups filed a federal lawsuit in Washington, D.C., challenging a Re...
Texas overtook California in the Fortune 500 rankings, flipping the script on corporate power and prompting fresh tax...
Regulators have cleared XRP as a digital commodity and spot ETFs are attracting flows, but the price has yet to rebou...
May CPI rose 0.5% from April, lifting the annual rate to 4.2%. Energy drove most of the move, while core inflation st...
President Donald Trump announced a peace deal with Iran, triggering sharp moves in oil, stocks, and currencies as inv...
Investors are reassessing policy bets after a hypothetical Warsh-led Fed signal sparked fresh market swings. The phra...
Fidelity’s Q1 2026 data show the average IRA balance climbing to $131,380 as contributions surge. Yet the gap between...